Difficulty: Medium
Average Score: 69%
Practice
This agent, which is used in the chemotherapy of Hodgkin's lymphoma, is potentially leukemogenic
Correct answer
D
Rationale
In this case, the correct answer is D) Procarbazine. Procarbazine is an alkylating agent that is commonly used in the chemotherapy treatment of Hodgkin's lymphoma. It is known to be potentially leukemogenic, meaning it has the potential to cause the development of leukemia as a long-term side effect of its use.
A) Dacarbazine is another chemotherapy drug used in the treatment of Hodgkin's lymphoma, but it is not specifically known to be leukemogenic.
B) Doxorubicin is an anthracycline chemotherapy drug commonly used in various cancers, but it is not associated with being leukemogenic in the same way as Procarbazine.
C) Prednisone is a corticosteroid that is often used in combination with other chemotherapy drugs, but it is not an alkylating agent and is not known to be leukemogenic.
Understanding the potential side effects and long-term risks associated with chemotherapy drugs is crucial in oncology. Healthcare providers must weigh the benefits of treatment against the potential risks to provide the best possible care for their patients. In the context of managing Hodgkin's lymphoma, knowledge of the specific side effect profiles of each drug helps in making informed decisions regarding treatment options.
A) Dacarbazine is another chemotherapy drug used in the treatment of Hodgkin's lymphoma, but it is not specifically known to be leukemogenic.
B) Doxorubicin is an anthracycline chemotherapy drug commonly used in various cancers, but it is not associated with being leukemogenic in the same way as Procarbazine.
C) Prednisone is a corticosteroid that is often used in combination with other chemotherapy drugs, but it is not an alkylating agent and is not known to be leukemogenic.
Understanding the potential side effects and long-term risks associated with chemotherapy drugs is crucial in oncology. Healthcare providers must weigh the benefits of treatment against the potential risks to provide the best possible care for their patients. In the context of managing Hodgkin's lymphoma, knowledge of the specific side effect profiles of each drug helps in making informed decisions regarding treatment options.